Patents by Inventor Claire Kinney

Claire Kinney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062375
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 3, 2022
    Applicants: TAKEDA VACCINES, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • Patent number: 10898565
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 26, 2021
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20200061151
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 27, 2020
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • Patent number: 10449231
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 22, 2019
    Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • Publication number: 20190151433
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 23, 2019
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Patent number: 10052374
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: August 21, 2018
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20170290884
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • Patent number: 9783579
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 10, 2017
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M Kinney, Jill A Livengood
  • Publication number: 20170049874
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 23, 2017
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20060292172
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 viruse) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Application
    Filed: June 9, 2006
    Publication date: December 28, 2006
    Inventors: Richard Kinney, Claire Kinney, Veronique Barban, Jean Lang, Bruno Guy
  • Publication number: 20060062803
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: February 16, 2001
    Publication date: March 23, 2006
    Inventors: Richard Kinney, Claire Kinney, Duane Gubler, Siritorn Butrapet, Natth Bhamarapravati